Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

被引：145
|
作者：
Brownlee, Wallace [1 ]
Bourdette, Dennis [2 ]
Broadley, Simon [3 ]
Killestein, Joep [4 ]
Ciccarelli, Olga [1 ,5 ]
机构：
[1] UCL Queen Sq Inst Neurol, Dept Neuroinflammat, Queen Sq MS Ctr, London, England
[2] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[3] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast Campus, Nathan, Qld, Australia
[4] Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands
[5] Univ Coll London Hosp NIHR Biomed Res Ctr, London, England
来源：
NEUROLOGY | 2020年 / 94卷 / 22期
关键词：
D O I：
10.1212/WNL.0000000000009507
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The emergence of novel coronavirus 2019 (COVID-19)(1)and the subsequent pandemic present a unique challenge to neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).
引用
收藏
页码：949 / 952
页数：4
相关论文
共 50 条
  • [31] Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis
    Hyun, Jae-Won
    Jang, Hyunmin
    Yu, JaeBin
    Park, Na Young
    Kim, Su-Hyun
    Huh, So-Young
    Kim, Woojun
    Park, Min Su
    Oh, Jeeyoung
    Park, Kee Duk
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2020, 16 (01): : 124 - 130
  • [32] Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Kim, Woojun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2020, 16 (03): : 355 - 368
  • [33] Efficacy and Safety of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP3 - NP4
  • [34] Quantitative Susceptibility Mapping in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Kim, W.
    Lee, J. E.
    Lee, K. S.
    Nam, Y.
    Jang, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 438 - 438
  • [35] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Tatchaporn Ongphichetmetha
    Jiraporn Jitprapaikulsan
    Sasitorn Siritho
    Natthapon Rattanathamsakul
    Thammachet Detweeratham
    Naraporn Prayoonwiwat
    Scientific Reports, 14
  • [36] Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach
    Ota, Miho
    Sato, Noriko
    Okamoto, Tomoko
    Noda, Takamasa
    Araki, Manabu
    Yamamura, Takashi
    Kunugi, Hiroshi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (06) : 515 - 520
  • [37] Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder
    Uzawa, A.
    Mori, M.
    Masuda, H.
    Ohtani, R.
    Uchida, T.
    Aoki, R.
    Kuwabara, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02): : 239 - 248
  • [38] Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis
    Hyun, J. -W.
    Jang, H.
    Yu, J.
    Park, N. Y.
    Kim, S. -H.
    Huh, S. -Y.
    Kim, W.
    Park, M. S.
    Oh, J.
    Park, K. D.
    Kim, H. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 401 - 402
  • [39] Prevalences and incidences of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea
    Kim, Jee-Eun
    Park, Sang-hyun
    Han, Kyungdo
    Kim, Ho-Jin
    Shin, Dong-wook
    Kim, Sung-Min
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP44 - NP44
  • [40] Sleep in multiple sclerosis and neuromyelitis optica spectrum disorder—the SEMN study
    Nise Alessandra Carvalho Sousa
    Carlos Mauricio Oliveira de Almeida
    Satiko Andrezza Ferreira Takano
    Siane Prado Lima Souza
    Ronaldo Marques Pontes Rabelo
    Sleep and Breathing, 2023, 27 : 2453 - 2458
12345